• PDF / 186,177 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 36 Downloads / 240 Views

DOWNLOAD

REPORT

73-5503/20/0860-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 22 Aug 2020 No. 860

1

Recommend Documents

Double CBT cost effective in acute leukaemia

157 46 115KB

Acute Myeloid Leukaemia

156 20 2MB

Factors Influencing Physician Recommendation for Imatinib Mesylate in Chronic Phase Chronic Myeloid Leukemia

135 64 14MB

Myeloid Neoplasm with t(8;22)(p11;q11): A Mimicker of Chronic Myeloid Leukaemia in Blast Crisis

149 4 640KB

Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion

142 44 421KB

Chronic Myelogenous Leukaemia

155 61 4MB

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

153 104 414KB

Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity

168 7 1MB

Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase:

151 4 1008KB

A Pilot Study on Probing of Imatinib Induced Platelet Dysfunction in Patients with Chronic Myeloid Leukemia-Chronic Phas

141 95 357KB

Treatment of chronic hepatitis C in young children cost effective

150 2 182KB

Cost-Effective

168 109 57MB